Stem Cell Reviews and Reports

, Volume 9, Issue 2, pp 184–189 | Cite as

NK and MSCs Crosstalk: The Sense of Immunomodulation and Their Sensitivity

  • Javier G. CasadoEmail author
  • R. Tarazona
  • F. M. Sanchez-Margallo


Several clinical trials are currently evaluating the safety and efficacy of mesenchymal stem cells (MSCs) in different diseases. The MSCs are guided by inflammatory mediators and specific interactions with immune cells occur, especially between MSCs and the cells of the innate immune system. At the present many of these interactions remain to be determined. This review summarizes the current knowledge in relation to the susceptibility of MSCs to NK cell mediated lysis as well as the immunomodulatory activity of MSCs and its control over NK cell function. Here we hypothesize that the inflammatory context will regulate the outcome of NK-MSC interactions.


NK cells Mesenchymal stem cells Immunomodulation Innate Response NK cell-mediated lysis 



Subprograma Inncorpora-Torres Quevedo 2011 (PTQ-11-04554). Thanks to V Alvarez and V Crisostomo for critical review and helpful comments. There is no conflict of interest with any financial organization regarding the material discussed in the manuscript.

Disclosure of Potential Conflicts of Interest

The authors declare no conflict of interest or financial interests.


  1. 1.
    Chen, X., Armstrong, M. A., & Li, G. (2006). Mesenchymal stem cells in immunoregulation. Immunology and Cell Biology, 84(5), 413–421.PubMedCrossRefGoogle Scholar
  2. 2.
    Stagg, J. (2007). Immune regulation by mesenchymal stem cells: two sides to the coin. Tissue Antigens, 69(1), 1–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Shi, Y., Su, J., Roberts, A. I., et al. (2012). How mesenchymal stem cells interact with tissue immune responses. Trends in Immunology, 33(3), 136–143.PubMedCrossRefGoogle Scholar
  4. 4.
    English, K., & Mahon, B. P. (2011). Allogeneic mesenchymal stem cells: agents of immune modulation. Journal of Cellular Biochemistry, 112(8), 1963–1968.PubMedCrossRefGoogle Scholar
  5. 5.
    Zhao, S., Wehner, R., Bornhauser, M., et al. (2010). Immunomodulatory properties of mesenchymal stromal cells and their therapeutic consequences for immune-mediated disorders. Stem Cells and Development, 19(5), 607–614.PubMedCrossRefGoogle Scholar
  6. 6.
    Gebler, A., Zabel, O., & Seliger, B. (2011). The immunomodulatory capacity of mesenchymal stem cells. Trends in Molecular Medicine, 18(2), 128–134.PubMedCrossRefGoogle Scholar
  7. 7.
    Rasmusson, I., Uhlin, M., Le, B. K., & Levitsky, V. (2007). Mesenchymal stem cells fail to trigger effector functions of cytotoxic T lymphocytes. Journal of Leukocyte Biology, 82(4), 887–893.PubMedCrossRefGoogle Scholar
  8. 8.
    Chen, L., Zhang, W., Yue, H., et al. (2007). Effects of human mesenchymal stem cells on the differentiation of dendritic cells from CD34+ cells. Stem Cells and Development, 16(5), 719–731.PubMedCrossRefGoogle Scholar
  9. 9.
    Ramasamy, R., Fazekasova, H., Lam, E. W., et al. (2007). Mesenchymal stem cells inhibit dendritic cell differentiation and function by preventing entry into the cell cycle. Transplantation, 83(1), 71–76.PubMedCrossRefGoogle Scholar
  10. 10.
    Prigione, I., Benvenuto, F., Bocca, P., et al. (2009). Reciprocal interactions between human mesenchymal stem cells and gammadelta T cells or invariant natural killer T cells. Stem Cells, 27(3), 693–702.PubMedCrossRefGoogle Scholar
  11. 11.
    Chen, L., Tredget, E. E., Wu, P. Y., & Wu, Y. (2008). Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. PLoS One, 3(4), e1886.PubMedCrossRefGoogle Scholar
  12. 12.
    Krasnodembskaya, A., Samarani, G., Song, Y., et al. (2012). Human mesenchymal stem cells reduce mortality and bacteremia in gram negative sepsis in mice in part by enhancing the phagocytic activity of blood monocytes. American Journal of Physiology. Lung Cellular and Molecular Physiology, 302(10), L1003–L1013.PubMedCrossRefGoogle Scholar
  13. 13.
    Tu, Z., Li, Q., Bu, H., & Lin, F. (2010). Mesenchymal stem cells inhibit complement activation by secreting factor H. Stem Cells and Development, 19(11), 1803–1809.PubMedCrossRefGoogle Scholar
  14. 14.
    Yagi, H., Soto-Gutierrez, A., Parekkadan, B., et al. (2010). Mesenchymal stem cells: mechanisms of immunomodulation and homing. Cell Transplantation, 19(6), 667–679.PubMedCrossRefGoogle Scholar
  15. 15.
    Deak, E., Seifried, E., & Henschler, R. (2010). Homing pathways of mesenchymal stromal cells (MSCs) and their role in clinical applications. International Reviews of Immunology, 29(5), 514–529.PubMedCrossRefGoogle Scholar
  16. 16.
    Rasmusson, I., Ringden, O., Sundberg, B., & Le, B. K. (2003). Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation, 76(8), 1208–1213.PubMedCrossRefGoogle Scholar
  17. 17.
    Gotherstrom, C., Lundqvist, A., Duprez, I. R., et al. (2011). Fetal and adult multipotent mesenchymal stromal cells are killed by different pathways. Cytotherapy, 13(3), 269–278.PubMedCrossRefGoogle Scholar
  18. 18.
    Sotiropoulou, P. A., Perez, S. A., Gritzapis, A. D., Baxevanis, C. N., & Papamichail, M. (2006). Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells, 24(1), 74–85.PubMedCrossRefGoogle Scholar
  19. 19.
    Spaggiari, G. M., Capobianco, A., Becchetti, S., Mingari, M. C., & Moretta, L. (2006). Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood, 107(4), 1484–1490.PubMedCrossRefGoogle Scholar
  20. 20.
    Poggi, A., Prevosto, C., Massaro, A. M., et al. (2005). Interaction between human NK cells and bone marrow stromal cells induces NK cell triggering: role of NKp30 and NKG2D receptors. Journal of Immunology, 175(10), 6352–6360.Google Scholar
  21. 21.
    Karre, K. (2008). Natural killer cell recognition of missing self. Nature Immunology, 9(5), 477–480.PubMedCrossRefGoogle Scholar
  22. 22.
    DelaRosa, O., Sanchez-Correa, B., Morgado, S., et al. (2011). Human adipose-derived stem cells impair NK cell function and exhibit low susceptibility to NK-mediated lysis. Stem Cells and Development, 21(8), 1333–1343.PubMedCrossRefGoogle Scholar
  23. 23.
    El, H. N., Moore, R., Heathcote, D., et al. (2011). The novel role of SERPINB9 in cytotoxic protection of human mesenchymal stem cells. Journal of Immunology, 187(5), 2252–2260.CrossRefGoogle Scholar
  24. 24.
    Hoogduijn, M. J., Roemeling-van, R. M., Korevaar, S. S., et al. (2011). Immunological aspects of allogeneic and autologous mesenchymal stem cell therapies. Human Gene Therapy, 22(12), 1587–1591.PubMedCrossRefGoogle Scholar
  25. 25.
    Bartholomew, A., Sturgeon, C., Siatskas, M., et al. (2002). Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Experimental Hematology, 30(1), 42–48.PubMedCrossRefGoogle Scholar
  26. 26.
    Noort, W. A., Kruisselbrink, A. B., in’t Anker PS, et al. (2002). Mesenchymal stem cells promote engraftment of human umbilical cord blood-derived CD34(+) cells in NOD/SCID mice. Experimental Hematology, 30(8), 870–878.PubMedCrossRefGoogle Scholar
  27. 27.
    Barry, F. P. (2003). Biology and clinical applications of mesenchymal stem cells. Birth Defects Research. Part C, Embryo Today, 69(3), 250–256.CrossRefGoogle Scholar
  28. 28.
    Jorgensen, C., Djouad, F., Apparailly, F., & Noel, D. (2003). Engineering mesenchymal stem cells for immunotherapy. Gene Therapy, 10(10), 928–931.PubMedCrossRefGoogle Scholar
  29. 29.
    Le, B. K. (2003). Immunomodulatory effects of fetal and adult mesenchymal stem cells. Cytotherapy, 5(6), 485–489.CrossRefGoogle Scholar
  30. 30.
    Ghannam, S., Pene, J., Torcy-Moquet, G., Jorgensen, C., & Yssel, H. (2010). Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. Journal of Immunology, 185(1), 302–312.CrossRefGoogle Scholar
  31. 31.
    Zheng, Z. H., Li, X. Y., Ding, J., Jia, J. F., & Zhu, P. (2008). Allogeneic mesenchymal stem cell and mesenchymal stem cell-differentiated chondrocyte suppress the responses of type II collagen-reactive T cells in rheumatoid arthritis. Rheumatology (Oxford, England), 47(1), 22–30.CrossRefGoogle Scholar
  32. 32.
    Gonzalez-Rey, E., Gonzalez, M. A., Varela, N., et al. (2010). Human adipose-derived mesenchymal stem cells reduce inflammatory and T cell responses and induce regulatory T cells in vitro in rheumatoid arthritis. Annals of the Rheumatic Diseases, 69(1), 241–248.PubMedCrossRefGoogle Scholar
  33. 33.
    Gonzalez-Rey, E., Anderson, P., Gonzalez, M. A., et al. (2009). Human adult stem cells derived from adipose tissue protect against experimental colitis and sepsis. Gut, 58(7), 929–939.PubMedCrossRefGoogle Scholar
  34. 34.
    Rasmusson, I., Le, B. K., Sundberg, B., & Ringden, O. (2007). Mesenchymal stem cells stimulate antibody secretion in human B cells. Scandinavian Journal of Immunology, 65(4), 336–343.PubMedCrossRefGoogle Scholar
  35. 35.
    Svobodova, E., Krulova, M., Zajicova, A., et al. (2012). The role of mouse mesenchymal stem cells in differentiation of naive T-cells into anti-inflammatory regulatory T-cell or proinflammatory helper T-cell 17 population. Stem Cells and Development, 21(6), 901–910.PubMedCrossRefGoogle Scholar
  36. 36.
    Spaggiari, G. M., Abdelrazik, H., Becchetti, F., & Moretta, L. (2009). MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2. Blood, 113(26), 6576–6583.PubMedCrossRefGoogle Scholar
  37. 37.
    Aggarwal, S., & Pittenger, M. F. (2005). Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood, 105(4), 1815–1822.PubMedCrossRefGoogle Scholar
  38. 38.
    Krampera, M., Cosmi, L., Angeli, R., et al. (2006). Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells, 24(2), 386–398.PubMedCrossRefGoogle Scholar
  39. 39.
    Yakar, I., Melamed, R., Shakhar, G., et al. (2003). Prostaglandin e(2) suppresses NK activity in vivo and promotes postoperative tumor metastasis in rats. Annals of Surgical Oncology, 10(4), 469–479.PubMedCrossRefGoogle Scholar
  40. 40.
    Chen, Y., Perussia, B., & Campbell, K. S. (2007). Prostaglandin D2 suppresses human NK cell function via signaling through D prostanoid receptor. Journal of Immunology, 179(5), 2766–2773.Google Scholar
  41. 41.
    Torres, D., Paget, C., Fontaine, J., et al. (2008). Prostaglandin D2 inhibits the production of IFN-gamma by invariant NK T cells: consequences in the control of B16 melanoma. Journal of Immunology, 180(2), 783–792.Google Scholar
  42. 42.
    Giuliani, M., Oudrhiri, N., Noman, Z. M., et al. (2011). Human mesenchymal stem cells derived from induced pluripotent stem cells down-regulate NK-cell cytolytic machinery. Blood, 118(12), 3254–3262.PubMedCrossRefGoogle Scholar
  43. 43.
    Ryan, J. M., Barry, F., Murphy, J. M., & Mahon, B. P. (2007). Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clinical and Experimental Immunology, 149(2), 353–363.PubMedCrossRefGoogle Scholar
  44. 44.
    Ren, G., Zhang, L., Zhao, X., et al. (2008). Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell, 2(2), 141–150.PubMedCrossRefGoogle Scholar
  45. 45.
    Almeida, C. R., Vasconcelos, D. P., Goncalves, R. M., & Barbosa, M. A. (2012). Enhanced mesenchymal stromal cell recruitment via natural killer cells by incorporation of inflammatory signals in biomaterials. Journal of the Royal Society, Interface, 9(67), 261–271.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Javier G. Casado
    • 1
    Email author
  • R. Tarazona
    • 2
  • F. M. Sanchez-Margallo
    • 1
  1. 1.Stem Cell Therapy UnitMinimally Invasive Surgery Centre Jesus UsonCaceresSpain
  2. 2.Immunology Unit, Department of PhysiologyUniversity of ExtremaduraCaceresSpain

Personalised recommendations